The impact of androgen deprivation therapy (ADT) on cardiovascular health 

Biographies:
Thomas E. Keane

Jehonathan H. Pinthus, MD, PhD, FRCSC is a surgical oncologist-urologist and ssociate Professor in the Department of Surgery Division of Urology McMaster University. He is heading a basic and translational research laboratory at McMaster University and his research interests relates to the patients individual host factors and metabolism that affects prostate cancer growth and response to therapy. Dr. Pinthus is the principle investigator on many research grants the most recent one being the Movember-Prostate Cancer Canada grant titled "Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC)" to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease. 

Related Content:

WATCH: Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

Everyday Urology - Assessment of Cardiovascular Risk With the Use of ADT for Prostate Cancer

Cardiovascular Effects of ADT for the Treatment of Prostate Cancer

Cardiovascular risks of ADT for prostate cancer